Clinical Trials on Haemophilus Infection

Total 61071 results

Indiana Hemophilia &Thrombosis Center, Inc.
Genentech, Inc.

Terminated

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

Haemophilic Pseudotumour

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Polio Immunisation | Haemophilus Influenzae Type B Immunisation | Rotavirus Immunisation

Thailand
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Russian Federation
Vabiotech
Vietstar Biomedical Research

Completed

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type B

Vietnam
Public Health England
Department of Health, United Kingdom; Institute of Child Health, London, England

Completed

Hepatitis B Vaccination in Infants (Infanrix)

Pneumococcal Disease | Meningococcal Disease | Diphtheria, Tetanus and Pertussis | Haemophilus Influenzae Serotype b Disease | Hepatitis b

United Kingdom
LG Life Sciences

Unknown

Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenza Type B
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
GlaxoSmithKline

Completed

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Germany
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
GlaxoSmithKline

Completed

Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Argentina
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Poliomyelitis Vaccines

Philippines
GlaxoSmithKline

Terminated

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Slovakia
GlaxoSmithKline

Completed

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
GlaxoSmithKline

Completed

Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Italy, Sweden, Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
PT Bio Farma
Hasan Sadikin General Hospital

Not yet recruiting

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Diphtheria Vaccine Adverse Reaction | Tetanus Vaccine Adverse Reaction | Pertussis Vaccine Adverse Reaction | Haemophilus Influenzae Type B Vaccine Adverse Reaction | Hepatitis B Vaccine Adverse Reaction

Indonesia
GlaxoSmithKline

Completed

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Singapore
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
Swedish Institute for Infectious Disease Control

Unknown

Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (Sero 2007)

Hepatitis B | Measles | Pertussis | Rubella | Mumps | Tetanus | Diphtheria | Polio | Haemophilus Influenzae Type B

Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Colombia, Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Healthy | Infant

Germany
Shantha Biotechnics Limited

Completed

Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type B

India
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Vietnam
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

India
GlaxoSmithKline

Completed

Neisseria Meningitidis Burden of Disease Study

Haemophilus Influenzae | Neisseria Meningitidis | Streptococcus Pneumoniae

Philippines, Vietnam
Al-Azhar University

Active, not recruiting

Evaluation of Xylitol Wipes as an Oral Hygiene Protocol for Haemophilic Children

Haemophilia

Egypt
University of Valencia

Unknown

Exercise Program to Improve Balance in Hemophilic Patients

Haemophilia

Spain
Novo Nordisk A/S

Completed

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) (explorer™6)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

France, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
GlaxoSmithKline

Completed

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Haemophilus Influenzae | Streptococcus Pneumoniae

Sweden
GlaxoSmithKline

Terminated

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Haemophilus Influenzae | Streptococcus Pneumoniae

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Pertussis | Tetanus | Diphtheria | Polio | Haemophilus Infections

United States
Sanofi

Completed

Immunogenicity and Safety of Pentaxim™ in an Indian Population

Pertussis | Tetanus | Diphtheria | Polio | Haemophilus Infections

India
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
Kirby Institute

Not yet recruiting

PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. (PATH)

Invasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
Novo Nordisk A/S

Completed

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

India, Morocco, South Africa, Oman
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

Spain
Investigación en Hemofilia y Fisioterapia

Completed

Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy

Haemophilia

Spain
Novo Nordisk A/S

Withdrawn

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

Clinical Trials on Haemophilus Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations